ADC Therapeutics (ADCT) Scheduled to Post Earnings on Monday

ADC Therapeutics (NYSE:ADCT) will be releasing its earnings data before the market opens on Monday, May 6th. Analysts expect ADC Therapeutics to post earnings of ($0.58) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last released its earnings results on Wednesday, March 13th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.56). ADC Therapeutics had a negative return on equity of 1,313.37% and a negative net margin of 344.15%. The firm had revenue of $16.79 million for the quarter, compared to analyst estimates of $16.58 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Stock Up 3.6 %

Shares of ADCT opened at $4.90 on Friday. The stock’s 50-day moving average price is $4.59 and its 200 day moving average price is $2.82. ADC Therapeutics has a 12-month low of $0.36 and a 12-month high of $6.04. The firm has a market capitalization of $405.77 million, a price-to-earnings ratio of -1.67 and a beta of 1.69.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Guggenheim restated a “buy” rating on shares of ADC Therapeutics in a research report on Friday, April 5th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of ADC Therapeutics in a report on Monday, April 15th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price objective on shares of ADC Therapeutics in a report on Thursday, March 14th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.